Researchers emulated a target trial using real-world data from a large, US-based, multi-centre electronic health record database to assess long-term outcomes of GLP-1RA use
insights to oxidative stress, inflammation, synaptic plasticity, liver/brain, and kidney/brain axes
Apr 16, 2026 7 min read Fat Loss Does Tesamorelin Selectively Target Visceral Adipose Tissue Without Systemic Effects
While some studies found that GLP-1 RAs demonstrated an improvement in excessive daytime sleepiness [58, 59], the pooled results did not ascertain statistical differences in ESS outcome, nor ODI, lowest SpO 2 , and TST90 outcomes
This scarcity may stem not only from insufficient priming but also from the functional inactivation of existing clones
Eli Lilly is targeting an FDA submission in late 2026